[go: up one dir, main page]

FI946083A0 - Antianginaaliset purinonit - Google Patents

Antianginaaliset purinonit

Info

Publication number
FI946083A0
FI946083A0 FI946083A FI946083A FI946083A0 FI 946083 A0 FI946083 A0 FI 946083A0 FI 946083 A FI946083 A FI 946083A FI 946083 A FI946083 A FI 946083A FI 946083 A0 FI946083 A0 FI 946083A0
Authority
FI
Finland
Prior art keywords
alkyl
purinones
antianginal
so2nr
pyrrolidino
Prior art date
Application number
FI946083A
Other languages
English (en)
Swedish (sv)
Other versions
FI946083L (fi
FI946083A7 (fi
Inventor
Nicholas Kenneth Terrett
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of FI946083L publication Critical patent/FI946083L/fi
Publication of FI946083A7 publication Critical patent/FI946083A7/fi
Publication of FI946083A0 publication Critical patent/FI946083A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Paper (AREA)
  • Signal Processing For Digital Recording And Reproducing (AREA)
  • Catalysts (AREA)
  • Vending Machines For Individual Products (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
FI946083A 1992-06-26 1993-06-18 Antianginaaliset purinonit FI946083A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929213623A GB9213623D0 (en) 1992-06-26 1992-06-26 Therapeutic agents
PCT/EP1993/001561 WO1994000453A1 (en) 1992-06-26 1993-06-18 Purinone antianginal agents

Publications (3)

Publication Number Publication Date
FI946083L FI946083L (fi) 1994-12-23
FI946083A7 FI946083A7 (fi) 1994-12-23
FI946083A0 true FI946083A0 (fi) 1994-12-23

Family

ID=10717795

Family Applications (1)

Application Number Title Priority Date Filing Date
FI946083A FI946083A0 (fi) 1992-06-26 1993-06-18 Antianginaaliset purinonit

Country Status (11)

Country Link
EP (1) EP0647227B1 (fi)
JP (1) JP2544903B2 (fi)
AT (1) ATE143961T1 (fi)
CA (1) CA2139109C (fi)
DE (1) DE69305344T2 (fi)
DK (1) DK0647227T3 (fi)
ES (1) ES2092316T3 (fi)
FI (1) FI946083A0 (fi)
GB (1) GB9213623D0 (fi)
GR (1) GR3021878T3 (fi)
WO (1) WO1994000453A1 (fi)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI951367A7 (fi) * 1994-03-28 1995-09-29 Japan Energy Corp Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit)
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
DE19501480A1 (de) * 1995-01-19 1996-07-25 Bayer Ag 9-substituierte 2-(2-n-Alkoxyphenyl)-purin-6-one
DE19501482A1 (de) * 1995-01-19 1996-07-25 Bayer Ag 2,9-disubstituierte Purin-6-one
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
JPH1087666A (ja) * 1996-09-18 1998-04-07 Kyorin Pharmaceut Co Ltd デュオカルマイシンｓａ及びその誘導体の製造中間体と製造方法
DE19702785A1 (de) * 1997-01-27 1998-07-30 Bayer Ag Neue cyclische Harnstoffderivate
CZ299633B6 (cs) 1997-04-25 2008-09-24 Pfizer Inc. Pyrazolopyrimidinony, meziprodukty pro jejich výrobu a farmaceutické a veterinární kompozice na jejich bázi
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
IL135462A0 (en) * 1997-11-12 2001-05-20 Bayer Ag 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
TR200003039T2 (tr) * 1998-04-20 2001-01-22 Pfizer Inc. Seksüel fonksiyon bozukluklarının tedavisi için pirazolopirimidinon cGMP PDE5 inhibitörleri
WO1999062905A1 (en) * 1998-06-03 1999-12-09 Almirall Prodesfarma, S.A. 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
DE19838300A1 (de) * 1998-08-24 2000-03-02 Bayer Ag 9-Dialkylaminopurinon-derivate
US6326379B1 (en) * 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823102D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823103D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
US6225315B1 (en) 1998-11-30 2001-05-01 Pfizer Inc Method of treating nitrate-induced tolerance
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
GB9924020D0 (en) 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
EA200200240A1 (ru) 1999-10-11 2002-10-31 Пфайзер Инк. 5-(2-ЗАМЕЩЕННЫЕ-5-ГЕТЕРОЦИКЛИЛСУЛЬФОНИЛПИРИД-3-ИЛ)-ДИГИДРОПИРАЗОЛО[4,3-d]ПИРИМИДИН-7-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ
DE50008549D1 (de) 1999-12-24 2004-12-09 Bayer Healthcare Ag Triazolotriazinone und ihre verwendung
WO2001078781A2 (en) * 2000-04-19 2001-10-25 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
US7335680B2 (en) 2001-12-20 2008-02-26 Laboratoires Serono Sa Pyrrolidine derivatives as prostaglandin modulators
GB0202282D0 (en) 2002-01-31 2002-03-20 Pfizer Ltd Treatment of male sexual dysfunction
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
DE60332387D1 (de) 2002-12-13 2010-06-10 Warner Lambert Co Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege
DK1620437T3 (da) 2003-04-29 2009-08-24 Pfizer Ltd 5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
EP1742950B1 (en) 2004-04-07 2008-12-17 Pfizer Limited Pyrazolo[4,3-d] pyrimidines
WO2006100557A1 (en) 2005-03-21 2006-09-28 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
DK1881985T3 (da) 2005-05-12 2011-02-14 Pfizer Vandfrie krystalliske former af N-Y1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-D]pyrimidin-3-carbonyl¨methansulfonamid
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1338235A (en) * 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
CA1303037C (en) * 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
EP0347146B1 (en) * 1988-06-16 1993-09-01 Smith Kline & French Laboratories Limited Fused pyrimidine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds

Also Published As

Publication number Publication date
JP2544903B2 (ja) 1996-10-16
GR3021878T3 (en) 1997-03-31
DK0647227T3 (da) 1996-11-18
FI946083L (fi) 1994-12-23
FI946083A7 (fi) 1994-12-23
ATE143961T1 (de) 1996-10-15
ES2092316T3 (es) 1996-11-16
DE69305344D1 (de) 1996-11-14
CA2139109A1 (en) 1994-01-06
DE69305344T2 (de) 1997-02-20
JPH07504681A (ja) 1995-05-25
EP0647227B1 (en) 1996-10-09
EP0647227A1 (en) 1995-04-12
WO1994000453A1 (en) 1994-01-06
CA2139109C (en) 1997-03-25
GB9213623D0 (en) 1992-08-12

Similar Documents

Publication Publication Date Title
FI946083A0 (fi) Antianginaaliset purinonit
CA2122360A1 (en) Quinazolinone Antianginal Agents
BR1100029A (pt) Agentes antiangìnicos de pirazolpirimidinonas
AU7915591A (en) Pyrazolopyrimidinone antianginal agents
FI950889A0 (fi) Antianginaaliset pyridopyrimidinoniaineet
DK0620215T3 (da) 1H-indol-3-acetamidderivater som sPLA2-inhibitorer
DK0646115T3 (da) Heterocykliske/cykliske aminderivater
NO934792D0 (no) Xantinderivater
NO932607L (no) Piperidinderivater og anvendelse av disse
DK0632036T3 (da) Amidderivater med antipypercholesteræmisk aktivitet, deres fremstilling og deres terapeutiske anvendelser
DK1044967T3 (da) 2-pyridinylguanidinurokinaseinhibitor
NO862621D0 (no) Fremgangsmaate ved fremstilling av pyridonkarboksylsyrederivater.
IE890177L (en) Piperidinyl derivatives
HU912567D0 (en) Preparation for decreasing uric acid contain in blood

Legal Events

Date Code Title Description
FD Application lapsed